Fluoro-deoxyglucose positron emission tomography imaging for the detection of occult disease in multiple myeloma.
Positron emission tomography with 2-deoxy-2-[18]fluoro-D-glucose (FDG-PET) imaging has been extensively used to detect occult metastatic malignant lesions in patients with carcinoma. We describe its use in three patients with multiple myeloma, each representing a particular clinical situation in which this imaging modality offered advantages over plain radiography, computerized tomography or magnetic resonance imaging. FDG-PET provides a whole body image showing sites of occult disease. This is of particular value in patients with non-secretory myeloma, solitary plasmacytoma or for those that relapse with focal disease following autologous or allogeneic stem cell transplantation.
Orchard
Kim
K
Department of Haematology, Royal Free and University College Medical School, Royal Free Campus, Clinical PET Centre, Guys, Kings and St. Thomas's Hospitals, London, UK. kho@soton.ac.uk
Barrington
Sally
S
Buscombe
John
J
Hilson
Andrew
A
Prentice
Hugh Grant
HG
Mehta
Atul
A
D000328:Adult; D001842:Bone and Bones / Q000000981:diagnostic imaging*; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000000981:diagnostic imaging*; D014055:Tomography, Emission-Computed
D019788:Fluorodeoxyglucose F18